Cited by 243COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.

Open access

Bramante, Carolyn T., Huling, Jared D., Tignanelli, Christopher J., Buse, John B., Liebovitz, David M., Nicklas, Jacinda M., Cohen, Kenneth, Puskarich, Michael A., Belani, Hrishikesh K., Proper, Jennifer L., Siegel, Lianne K., Klatt, Nichole R., Odde, David J., Luke, Darlette G., Anderson, Blake, Karger, Amy B., Ingraham, Nicholas E., Hartman, Katrina M., Rao, Via, Hagen, Aubrey A., Patel, Barkha, Fenno, Sarah L., Avula, Nandini, Reddy, Neha V., Erickson, Spencer M., Lindberg, Sarah, Fricton, Regina, Lee, Samuel, Zaman, Adnin, Saveraid, Hanna G., Tordsen, Walker J., Pullen, Matthew F., Biros, Michelle, Sherwood, Nancy E., Thompson, Jennifer L., Boulware, David R., Murray, Thomas A.·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2201662PMC PMC9945922

Open this paper in CoChat — free account

Abstract

BACKGROUND: Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. METHODS: In this phase 3, double-blind, randomized, placebo-controlled trial, we used a 2-by-3 factorial design to test the effectiveness of three repurposed drugs - metformin, ivermectin, and fluvoxamine - in preventing serious SARS-CoV-2 infection in nonhospitalized adults who had been enrolled within 3 days after a confirmed diagnosis of infection and less than 7 days after the onset of symptoms. The patients were between the ages of 30 and 85 years, and all had either overweight or obesity. The primary composite end point was hypoxemia (≤93% oxygen saturation on home oximetry), emergency department visit, hospitalization, or death. All analyses used controls who had undergone concurrent randomization and were adjusted for SARS-CoV-2 vaccination and receipt of other trial medications. RESULTS: A total of 1431 patients underwent randomization; of these patients, 1323 were included in the primary analysis. The median age of the patients was 46 years; 56% were female (6% of whom were pregnant), and 52% had been vaccinated. The adjusted odds ratio for a primary event was 0.84 (95% confidence interval [CI], 0.66 to 1.09; P = 0.19) with metformin, 1.05 (95% CI, 0.76 to 1.45; P = 0.78) with ivermectin, and 0.94 (95% CI, 0.66 to 1.36; P = 0.75) with fluvoxamine. In prespecified secondary analyses, the adjusted odds ratio for emergency department visit, hospitalization, or death was 0.58 (95% CI, 0.35 to 0.94) with metformin, 1.39 (95% CI, 0.72 to 2.69) with ivermectin, and 1.17 (95% CI, 0.57 to 2.40) with fluvoxamine. The adjusted odds ratio for hospitalization or death was 0.47 (95% CI, 0.20 to 1.11) with metformin, 0.73 (95% CI, 0.19 to 2.77) with ivermectin, and 1.11 (95% CI, 0.33 to 3.76) with fluvoxamine. CONCLUSIONS: None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19. (Funded by the Parsemus Foundation and others; COVID-OUT ClinicalTrials.gov number, NCT04510194.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2201662

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial
Reis, G., Silva, E. A. D. S. M., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., dos Santos, C. V. Q., Neto, A. D. D. F., Callegari, E. D., Savassi, L. C. M., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100142 · Cited by 65
Retracted
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
(2013) · JAMA · doi:10.1001/jama.2013.281053 · Cited by 30,732
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Untitled work
(2020) · PubMed · Cited by 2,642
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,349
Self-citation
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al‐Salameh, A., Allix, I., Amadou, C., Arnault, G., Baudoux, F., Bauduceau, B., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05180-x · Cited by 834
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
Skipper, C. P., Pastick, K. A., Engen, N. W., Bangdiwala, A. S., Abassi, M., Lofgren, S. M., Williams, D. A., Okafor, E. C., Pullen, M. F., Nicol, M. R., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4207 · Cited by 538
Self-citation
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
Lenze, E. J., Mattar, C., Zorumski, C. F., Stevens, A., Schweiger, J., Nicol, G. E., Miller, J. P., Yang, L., Yingling, M., Avidan, M. S., et al. (2020) · JAMA · doi:10.1001/jama.2020.22760 · Cited by 495

Flagged first, then by citations

Show all 50 references

1 of the 50 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 243

An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Leone, M., & Barzilai, N. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5138 · Cited by 10
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
Song, Z., Huang, Q.-M., Xu, S.-S., Zhou, J.-B., & Zhang, C. (2024) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-024-00633-6 · Cited by 7
Effects of different treatments for type 2 diabetes mellitus on mortality of coronavirus disease from 2019 to 2021 in China: a multi-institutional retrospective study
Xu, K., He, W., Yu, B., Zhong, K., Zhou, D., & Wang, D. W. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00183-1 · Cited by 6
The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID
Reis, G., Silva, E. A. D. S. M., Silva, D. C. M., Thabane, L., Ferreira, T. S., Reis, L. L. F., Almeida, A. P. F. G., Amaral, M. M., Savassi, L. C. M., Campos, V. H. D. S., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03959 · Cited by 6
Retracted
Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before–after Analysis
Tsiakalos, A., Ziakas, P. D., Polyzou, E., Schinas, G., & Akinosoglou, K. (2023) · Microorganisms · doi:10.3390/microorganisms11082073 · Cited by 6
Clinical efficacy of N-acetylcysteine for COVID-19: A systematic review and meta-analysis of randomized controlled trials
Liu, T., Wu, J., Huang, P., Tsai, Y., Hsu, W., Chuang, M., Tang, H.-J., & Lai, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25179 · Cited by 6
Risk of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Among Patients with Type 2 Diabetes Mellitus on Anti-Hyperglycemic Medications
Olawore, O., Turner, L., Evans, M. D., Johnson, S., Huling, J. D., Bramante, C. T., Buse, J. B., & Stürmer‎, T. (2024) · Clinical Epidemiology · doi:10.2147/clep.s458901 · Cited by 6
Self-citation
Metformin as adjunctive therapy in combination with multidrug treatment for multibacillary leprosy: A protocol for a randomized double-blind, controlled Phase 2 trial in Indonesia (MetLep Trial)
Krismawati, H., Muchtar, S. V., Rahardjani, M., Utami, N. N., Oktaviani, M., Puspatriani, K., Hasvitasari, D. E., Imbiri, N., Hasvitasari, D. E., Fajrianti, D. R., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19455.1 · Cited by 9
The importance of patient-partnered research in addressing long COVID: Takeaways for biomedical research study design from the RECOVER Initiative’s Mechanistic Pathways taskforce
Kim, C., Chen, B. K., Mohandas, S., Rehman, J., Sherif, Z. A., Coombs, K., RECOVER Mechanistic Pathways Task Force, & Initiative, O. B. O. T. R. (2023) · eLife · doi:10.7554/elife.86043 · Cited by 6
The prevention and treatment of COVID-19 in patients treated with hemodialysis
Zeng, B., Zhou, J., Peng, D., Dong, C., & Qin, Q. (2023) · European journal of medical research · doi:10.1186/s40001-023-01389-9 · Cited by 8
Estimating the effect of realistic improvements of metformin adherence on COVID-19 mortality using targeted machine learning
Qiu, S., Hubbard, A., Gutiérrez, J. P., Pimpale, G., Juárez-Flores, A., Ghosh, R., Ascencio-Montiel, I. D. J., & Bertozzi, S. (2024) · Global Epidemiology · doi:10.1016/j.gloepi.2024.100142 · Cited by 6
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections
Hurwitz, S. J., De, R., LeCher, J. C., Downs-Bowen, J. A., Goh, S. L., Zandi, K., McBrayer, T. R., Amblard, F., Patel, D. J., Kohler, J. J., et al. (2024) · Viruses · doi:10.3390/v16040651 · Cited by 6
Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia del Sol, I. T., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.2570 · Cited by 8
Self-citation
Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action
Liang, Y., Quan, X., Gu, R., Meng, Z., Gan, H. K., Wu, Z., Sun, Y., Pan, H., Han, P., Liu, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35988 · Cited by 7
Metformin as antiviral therapy protects hyperglycemic and diabetic patients
Wang, X., Zheng, X., Ge, H., Cui, N., Lin, L., Yue, M., Zhu, C., Zhou, Q., Song, P., Shang, X., et al. (2025) · mBio · doi:10.1128/mbio.00634-25 · Cited by 5
Macrocyclic Compounds: Unveiling Their Distinctive Antiviral Advantages in Medicinal Research
Yang, X., Jiao, Z., Fan, C., Ye, W., Lv, S., Wang, X., Wang, C., Zhang, K., Ke, X., & Zhou, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02430 · Cited by 5
Infection Rates and Impact of Glucose Lowering Medications on the Clinical Course of COVID-19 in People with Type 2 Diabetes: A Retrospective Observational Study
Mannucci, F., Vitturi, G., Benacchio, L., Sbrogiò, L. G., Bano, F., Lapolla, A., Piarulli, F., Giron, M. C., Avogaro, A., & Fadini, G. P. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s385646 · Cited by 5
Ongoing Need for Clinical Trials and Contemporary End Points for Outpatient COVID-19
Lee, T. C., & Boulware, D. R. (2022) · Annals of Internal Medicine · doi:10.7326/m22-3317 · Cited by 5
Self-citation
At a Higher Dose and Longer Duration, Ivermectin Still Not Effective Against COVID-19
Bibbins-Domingo, K. B., & Malani, P. (2023) · JAMA · doi:10.1001/jama.2023.1922 · Cited by 5
Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: a retrospective cohort study using real-world data
Wang, H., Wei, Y., Hung, C. T., Jiang, X., Li, C., Jia, K. M., Leung, E. Y. M., Yam, C. H. K., Chow, T. Y., Zhao, S., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100716 · Cited by 5
Analogies between COVID-19 and Preeclampsia: Focus on Therapies
Giardini, V., Gambacorti-Passerini, C. B., Casati, M., Carrer, A., & Vergani, P. (2023) · International Journal of Translational Medicine · doi:10.3390/ijtm3020015 · Cited by 5
Integrative Analysis of Functional Genomic Screening and Clinical Data Identifies a Protective Role for Spironolactone in Severe COVID-19
Cousins, H. C., Kline, A. S., Wang, C., Qu, Y., Zengel, J. R., Carette, J. E., Wang, M., Altman, R. B., Luo, Y., & Cong, L. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100503 · Cited by 5
Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand
Mikamo, H., Takahashi, S., Yamagishi, Y., Hirakawa, A., Harada, T., Nagashima, H., Noguchi, C., 増古, 賢., Maekawa, H., Kashii, T., et al. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.12.012 · Cited by 5
Is Metformin Use Associated with a More Favorable COVID-19 Course in People with Diabetes?
Silverii, G. A., Fumagalli, C., Rozzini, R., Milani, M., Mannucci, E., & Marchionni, N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071874 · Cited by 5
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo
Rothman, R. L., Stewart, T. G., Mourad, A., Boulware, D. R., McCarthy, M. W., Thicklin, F., del Sol, I. T. G., Garcia, J. L., Bramante, C. T., Shah, N. S., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.39332 · Cited by 7
Self-citation
When Characteristics of Clinical Trials Require Per-Protocol as Well as Intention-to-Treat Outcomes to Draw Reliable Conclusions: Three Examples
Scheim, D. E., Aldous, C. M., Osimani, B., Fordham, E. J., & Hoy, W. E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113625 · Cited by 5
Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical TrialPreprint
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Lim, S. C., Cohen, J. B., Kavtaradze, D., Amon, A. P., Gabriel, A., Gentile, N., et al. (2022) · medRxiv · doi:10.1101/2022.12.15.22283488 · Cited by 5
Self-citation
Emerging host-targeted antivirals for respiratory viruses: antivirals targeting virus elements versus host mechanisms
Matsunaga, N. (2026) · Next research. · doi:10.1016/j.nexres.2026.101311 · Cited by 4
Preventing Long COVID With Metformin
Bramante, C. T., & Boulware, D. R. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf700 · Cited by 4
Self-citation
Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update
Bonnet, U., & Juckel, G. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2374-2218 · Cited by 5
Ivermectin’s neuroprotective effects decrease with prolonged use after cerebral ischemia/reperfusion
Rezaei, S., Babataheri, S., & Soraya, H. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01657-z · Cited by 4
AMP kinase: A promising therapeutic drug target for post-COVID-19 complications
Ashraf, M. S., Tuli, K., Moiz, S., Sharma, S. K., Sharma, D., & Adnan, M. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123202 · Cited by 4
The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death
Mateja, A., Chu, E., Murray, T. A., Bramante, C. T., Moser, C., Givens, N., Abdelghany, M., Blair, C., Chen, S., Lat, P. K., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf282 · Cited by 4
Self-citation
An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
Sarojvisut, P., Apisarnthanarak, A., Jantarathaneewat, K., Sathitakorn, O., Pienthong, T., Mingmalairak, C., Warren, D. K., & Weber, D. J. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0127 · Cited by 4
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
Cheng, S.-L., Wang, P.-H., Chang, C., Wang, H.-H., Wang, C.-J., & Chiu, K. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s392708 · Cited by 4
Treating COVID-19: Targeting the Host Response, Not the Virus
Fedson, D. S. (2023) · Life · doi:10.3390/life13030712 · Cited by 4
Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium
Servais, T., Laurent, F., Roland, T., Rossi, C., Groote, E. D., Godart, V., Repetto, E. C., Ponchon, M., Chasseur, P., Crenier, L., et al. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.08.002 · Cited by 4
Effects of Metformin on COVID-19 Patients with Type 2 Diabetes: A Retrospective Study
Guo, Z., Gao, Y., Xie, E., Ye, Z., Li, Y., Zhao, X., Shen, N., & Zheng, J. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s417925 · Cited by 4
Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases
Bonnet, U., Juckel, G., & Kuhn, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1305184 · Cited by 4
Metformin and Infections: What Is the Next Step in This Decades-Long Story?
Goto, M., & Perencevich, E. N. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac903 · Cited by 4
A Twisting Tale of Misinformation: Should Ivermectin be Approved as a Treatment for COVID-19 Disease?
Shafiee, A., Athar, M. M. T., & Mozhgani, S. (2023) · Future Virology · doi:10.2217/fvl-2023-0006 · Cited by 4
A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)
Siripongboonsitti, T., Tawinprai, K., Avirutnan, P., Jitobaom, K., & Auewarakul, P. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.03.030 · Cited by 3
The effect of intravenous lipid emulsion (ILE) on the pharmacokinetic/toxicokinetic dispositions of ivermectin and carprofen in rabbits
Akyol, B. A., & Gökbulut, C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02738-5 · Cited by 3
Strategies used for the COVID-OUT decentralized trial of outpatient treatment of SARS-CoV-2
Avula, N., Kakach, D., Tignanelli, C. J., Liebovitz, D., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H., Buse, J. B., Klatt, N. R., et al. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.668 · Cited by 3
Self-citation
Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
Papić, I., Bistrović, P., Krečak, I., Hadžiabdić, M. O., & Lucijanić, M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237868 · Cited by 3
Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease
Yoon, H., & Pirofski, L. (2024) · Current topics in microbiology and immunology · doi:10.1007/82_2024_275 · Cited by 3
Preadmission Metformin Use Is Associated with Reduced Mortality in Patients with Diabetes Mellitus Hospitalized with COVID-19
Harmon, D. C., Levene, J., Rutlen, C., White, E. S., Freeman, I., & Lapidus, J. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08864-x · Cited by 3
Metformin for covid-19: systematic review and meta-analysis of randomised controlled trials
Chowdhury, S. R., Islam, N., Zhou, Q., Hasan, M. K., Chowdhury, M. R., Siemieniuk, R. A. C., Agarwal, A., Brignardello‐Petersen, R., Agoritsas, T., Vandvik, P. O., et al. (2025) · BMJ Medicine · doi:10.1136/bmjmed-2024-001126 · Cited by 5
Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses
Renz, A., Hohner, M., Jami, R., Breitenbach, M., Josephs‐Spaulding, J., Dürrwald, J., Best, L., Dulière, V., Mialon, C., Bader, S. M., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08148-y · Cited by 4
Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection
Yu, C., Carvalho, A. F., Thompson, T., Tsai, T., Tseng, P., Hsu, C., Tu, Y., Yang, S., Hsu, T., Yeh, T., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054088 · Cited by 3
Age- and Severity-Associated Humoral Immunity Response in COVID-19 Patients: A Cohort Study from Wuhan, China
Zhu, A., Liu, M., Li, Y., Lei, Q., Wu, Q., Lin, M., Lai, D., Lu, L., Yu, S., Guo, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195974 · Cited by 3
Effect of Higher-Dose Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical TrialPreprint
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators, & Naggie, S. (2023) · medRxiv · doi:10.1101/2023.09.12.23295424 · Cited by 3
Case–control study on risk factors for in-hospital mortality in patients with severe COVID-19
Wu, K., Yin, L., Han, J., Cai, Q.-H., Guo, Y., Jin, X., Wu, J., & Cheng, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1424720 · Cited by 2
Preapproval and postapproval diagnostic test accuracy of food and drug administration–authorized rapid antigen SARS-CoV-2 tests used according to instruction: a systematic review and meta-analysis
Damkjær, M. W., Laursen, D. R. T., Elkjær, M., Gerke, O., Lundh, A., Hróbjartsson, A., & Schroll, J. B. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.07.009 · Cited by 2
Trial characteristics, methods and reported challenges of decentralised clinical trials: a scoping review
Cussen, A., & Littler, K. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106823 · Cited by 6
Mitochondrial OXPHOS restricts SARS-CoV-2 replication
Albrecht, Y. E. S., Morrow, R. M., Kenney, D., Olali, A. Z., Wacquiez, A., Chehadeh, N., Cen, Z., Haltom, J., Chen, I. G., Ranshing, S., et al. (2026) · Science Advances · doi:10.1126/sciadv.adz3081 · Cited by 2
Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID
Reis, G., Silva, E. A. D. S. M., Silva, D. C. M., Thabane, L., Ferreira, T. S., Reis, L. L. F., Almeida, A. P. F. G. D., Amaral, M. M., Savassi, L. C. M., Campos, V. H. D. S., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-02144 · Cited by 2
Outpatient medications associated with protection from COVID-19 hospitalization
Sandhu, H. S., Lambert, J., Steckler, Z., Park, L., Stromberg, A. J., Ramírez, J. A., & Yang, C. J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282961 · Cited by 2
Metformin in COVID-19: Is There a Role Beyond Glycemic Control?
Nagendra, L., Bhattacharya, S., Kalra, S., & Kapoor, N. (2023) · Intern J Endocrinol Metab · doi:10.5812/ijem-132965 · Cited by 2
Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study
da Silva, N. B. L., Rocha, R. P. S., Andrade, A. C. D. S., Terças‐Trettel, A. C. P., & Muraro, A. P. (2023) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-549720230026 · Cited by 2
Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study
Glebov, O. O., Mueller, C., Stewart, R. J., Aarsland, D., & Perera, G. (2023) · BMC Medicine · doi:10.1186/s12916-023-02877-9 · Cited by 2
Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study
Jang, H. N., Moon, S. J., Jung, J., Han, K.-D., Rhee, E., & Lee, W. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1857 · Cited by 2
COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19
Claveau, S., Mahmood, F., Amir, B. A., Kwan, J. J. W., White, C., Vipond, J., & Iannattone, L. (2024) · Current Oncology · doi:10.3390/curroncol31090393 · Cited by 2
Death caused by transdermal ivermectin poisoning: A case report and literature review
Yin, H., Zhang, P., Chen, Y., Kong, B.-B., Zhang, C., & Wu, S. (2025) · Journal of International Medical Research · doi:10.1177/03000605251377690 · Cited by 2
Antidiabetic Treatment before Hospitalization and Admission Parameters in Patients with Type 2 Diabetes, Obesity, and SARS-CoV-2 Viral Infection
Reștea, P.-A., Muresan, M. E., Voicu, A., Jurca, T., Pallag, A., Marian, E., Vicaș, L. G., Jeican, I. I., & Crivii, C. B. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030392 · Cited by 2
Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study
Trkulja, V., & Kodvanj, I. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03479-3 · Cited by 2
The Penn Medicine COVID-19 Therapeutics Committee—Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency
Anesi, G. L., Degnan, K. O., Dutcher, L. S., Saw, S., Maguire, C., Binkley, A., Patel, S., Athans, V., Barton, T. D., Binkley, S., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad428 · Cited by 2
Precision Medicine for COVID-19 Based on the Inflammatory Response
Kothalkar, A. D., Jambhale, D., Hingane, V., Gore, S., & Deshpande, S. (2024) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001371 · Cited by 2
Psychopharmacotherapy factor in the variants of COVID-19 course in psychiatric inpatients
Незнанов, Н. Г., Васильевич, Л. О., Shabelnik, A. V., Azarova, L. A., Lutova, N. B., Bocharova, M., & Sorokin, M. Y. (2024) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2024-856 · Cited by 2
There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
Trkulja, V. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.11.016 · Cited by 2
Why we should not recommend or offer fluvoxamine to COVID-19 patients?
Trkulja, V. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03447-3 · Cited by 2
The Use of Ivermectin in the Treatment of COVID-19
Shukla, A. K., & Misra, S. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08104-8 · Cited by 2
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: author's response
Deng, J., Affan, E., Garcia, C., Heybati, K., & Zhou, F. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.03.026 · Cited by 2
Metabolic Modeling Elucidates Phenformin and Atpenin A5 as Broad-Spectrum Antiviral DrugsPreprint
Renz, A., Hohner, M., Breitenbach, M., Josephs‐Spaulding, J., Dürrwald, J., Best, L., Jami, R., Μαρίνος, Γ., Cabreiro, F., Dräger, A., et al. (2023) · Preprints.org · doi:10.20944/preprints202210.0223.v2 · Cited by 1
A Comparison of Recruitment Methods for a Remote, Nationwide Clinical Trial for COVID-19 Treatment
Hartman, K. M., Patel, B., Rao, V., Hagen, A. A., Saveraid, H. G., Fricton, R., Lee, S., Snyder, A. T., Pullen, M. F., Boulware, D. R., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae224 · Cited by 1
Self-citation
Environmental factors capable of broadly interfering with nutritional lifespan extension paradigms
Li, S., Stuhr, N. L., Ahsan, F. M., Zhou, Y., Yerevanian, A. I., Rotti, J. F., Dao, K., Jain, M., & Soukas, A. A. (2025) · iScience · doi:10.1016/j.isci.2025.112827 · Cited by 1
A Systematic Assessment of Drug Repurposing Efforts Against COVID‐19: Limited Successes and Key Challenges
Riedel, A., Ruth, P., Loeffler, M. W., & Stransky, N. (2025) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/3796111 · Cited by 2
Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial
Kandel, C. E., Biondi, M. J., Gillrie, M. R., Taylor, M., Barber, B., Amiri, L., Robinson, T., Powis, J. E., Adhikari, N. K. J., Kozak, R. A., et al. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.08.003 · Cited by 1
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
Hashmi, M., Haniffa, R., Jayakumar, D., Beane, A., Lorenzi, E., Berry, L. R., Khoso, M. N., Khan, Q. A., Kumar, A., Kidwai, A. A., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007134 · Cited by 1
Bone Marrow Mesenchymal Stem Cell Extracellular Vesicle Treatment of Respiratory Failure from COVID-19: Endpoint Analysis of Expanded Access Safety Trial
Sengupta, V., Qian, S., Ransom, J. T., Suzuki, S., Park, D. Y., Melson, T. I., Williams, B. P., Walsh, J. J., Awili, M., Mann, J. M., et al. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11137-1 · Cited by 2
Identification of efflux inhibitors through a drug repurposing strategy in Candida albicans
Marques, D., Costa, S. S., & Rodrigues, L. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1798450 · Cited by 1
Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents
Dechtman, I.-D., Ankory, R., Sokolinsky, K., Krasner, E., Weiss, L., & Gal, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11061577 · Cited by 1
Association Between Selective Serotonin Reuptake Inhibitors Prevalent Use and COVID-19–Related Mortality
Osores, P. I., Vivacqua, M. N., Vázquez, C., Marciano, S., Giunta, D. H., & Faccioli, J. L. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001721 · Cited by 1
Reduced risk of mortality among COVID-19 patients with in-hospital selective serotonin reuptake inhibitor administration
Hasse, A., Korwek, K. M., & Poland, R. E. (2023) · Journal of Pharmaceutical Health Services Research · doi:10.1093/jphsr/rmad031 · Cited by 1
Case Report on High Dose Lithium Treatment for Post-COVID Depression, Recurrent Fevers, and Skin Lesions
Massoumi, L., & Rosenbaum, A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4489 · Cited by 1
Prevalence, Predictors, and Outcomes of Type 2 NSTEMI in Hospitalized Patients With COVID‐19
Patel, S., Visotcky, A. M., Devine, A., Kode, V., Kotlo, S., Aljadah, M. M., Sparapani, R., & Kulinski, J. P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032572 · Cited by 1
Framework of the strengths and challenges of clinically integrated trials: An expert panel report
Peters, A. E., Jones, W. S., Anderson, B., Bramante, C. T., Broedl, U. C., Hornik, C. P. V., Kehoe, L. S., Knowlton, K. U., Krofah, E., Landray, M., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.05.009 · Cited by 1
Self-citation
Klotho Deficiency in Severe COVID-19: A Unifying Hypothesis
Campos‐Obando, N., Zillikens, M. C., & Macaya, R. F. (2024) · COVID · doi:10.3390/covid4120129 · Cited by 1
Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
Patwekar, M., Patwekar, F., Kumar, J. P., Prasad, P. D., Malik, N., Badarinath, A. V., Parupathi, P. R., Reddy, K. T. K., Elumalai, S., & Samad, Z. A. A. (2025) · BIO Integration · doi:10.15212/bioi-2024-0047 · Cited by 2
The crucial role of small heat shock proteins in prostate cancer: mechanisms and new therapeutic perspectives
Feng, Y., Ma, J., Zhu, B., Yue, D., & Wang, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2025.195090 · Cited by 2
Genetics of SSRI antidepressant use and relationship to psychiatric and medical traits
Levey, D. F., Galimberti, M., Deak, J. D., Gupta, P., Empke, S. L. L., Adhikari, K., Harrington, K. M., Quaden, R. M., Gaziano, J. M., Program, V. M. V., et al. (2025) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2025.100500 · Cited by 1
Prevalência do uso de ivermectina para prevenir COVID-19 durante a pandemia em Mato Grosso: estudo transversal de base domiciliar
da Silva, N. B. L., Rocha, R. P. S., Andrade, A. C. D. S., Terças‐Trettel, A. C. P., & Muraro, A. P. (2023) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-549720230026.2 · Cited by 1
Investigating the impact of metformin on severity of COVID‐19 in patients with Type 2 diabetes mellitus: Focusing on laboratory findings
Taheri, R., Shahrokhi, S. Z., Amjadi, Z., & Kazerouni, F. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.441
Antiviral Theory Might Help to Develop Drug-Resistance-Free Antimalarial Drugs
Li, G.-D. (2023) · OALib · doi:10.4236/oalib.1110505 · Cited by 1
"The Cytotoxicity of Metformin and Misoprostol Overwhelms their Antiviral Activity in SARS-CoV-2-Infected Vero-E6 Cell Culture"
Abdelmissih, S. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.52.008281 · Cited by 1
Ivermectin for COVID-19: The 2022 Update
Manu, P. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001577 · Cited by 1
Three Years of COVID-19 and the APJPH
Binns, C. W., & Low, W. Y. (2022) · Asia Pacific Journal of Public Health · doi:10.1177/10105395221132915 · Cited by 1
Ivermectin Treatment for Covid-19
Barus, R., Gautier, S., & Wabont, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2207995 · Cited by 1
Ivermectin and the Emergence of Long COVID
Manu, P. (2023) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001607 · Cited by 1
Initiation of antidepressants in patients infected with SARS-COV-2: Don't forget Caution for “Paradoxical” Anxiety/Jitteriness syndrome—Commentary: Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution
Bonnet, U. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1095244 · Cited by 1

Authors: Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., Siegel, L. K., Klatt, N. R., Odde, D. J., Luke, D. G., Anderson, B., Karger, A. B., Ingraham, N. E., Hartman, K. M., Rao, V., Hagen, A. A., Patel, B., Fenno, S. L., Avula, N., Reddy, N. V., Erickson, S. M., Lindberg, S., Fricton, R., Lee, S., Zaman, A., Saveraid, H. G., Tordsen, W. J., Pullen, M. F., Biros, M., Sherwood, N. E., Thompson, J. L., Boulware, D. R., & Murray, T. A.
Affiliations: University of Minnesota (US)
University of North Carolina at Chapel Hill (US)
Northwestern University (US)
ORCID: Bramante, Carolyn T.
Huling, Jared D.
Tignanelli, Christopher J.
Buse, John B.
Liebovitz, David M.
Nicklas, Jacinda M.
Puskarich, Michael A.
Belani, Hrishikesh K.
Proper, Jennifer L.
Siegel, Lianne K.
Klatt, Nichole R.
Odde, David J.
Anderson, Blake
Karger, Amy B.
Ingraham, Nicholas E.
Hartman, Katrina M.
Avula, Nandini
Reddy, Neha V.
Erickson, Spencer M.
Lindberg, Sarah
Lee, Samuel
Zaman, Adnin
Pullen, Matthew F.
Biros, Michelle
Sherwood, Nancy E.
Boulware, David R.
Murray, Thomas A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-08-18
Volume: 387
Issue: 7
Pages: 599-610
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2201662
PMC: PMC9945922
OpenAlex: W4292148078
Cited by: 242
References: 50
Citations by year: 2026: 19 · 2025: 31 · 2024: 63 · 2023: 94 · 2022: 35
FWCI: 27.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: UnitedHealth Group Foundation
Fast Grants
National Center for Advancing Translational Sciences (KL2TR002492, UL1TR002494)
National Institute of Diabetes and Digestive and Kidney Diseases (DK124654-01A1)
Rainwater Charitable Foundation
The Parsemus Foundation
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
Keywords: COVID-19 pandemic, SARS-CoV-2, metformin, ivermectin, fluvoxamine, drug repurposing, antiviral therapy, disease progression prevention, hypoxemia, hospitalization, mortality, obesity, overweight, emergency department visits, COVID-19 vaccination
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Drug Treatment, Adult, Aged, Aged, 80 and over, Hypoxia, Double-Blind Method, Female, Humans, Ivermectin, Male, Metformin, Middle Aged, Obesity, Pregnancy, Pregnancy Complications, Infectious, Fluvoxamine, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks